DENVER, CO, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Mohyuddin Mirza has joined the company as the Botany Specialist.
Dr. Mohyuddin Mirza has over three decades of experience in the management of greenhouse crops from farm to consumers including Echinacea, Rhodeola, and Cannabis and has made a significant economical impact on the botanical products industries in Alberta, Canada. He pioneered the industry by introducing hydroponics and soilless crop production to indoor growing and played a pivotal role in growing the greenhouse industry from a $25 million to $160 million business from 1980 to 2014. He is the recipient of Alberta Agriculture Hall of Fame in 2014
“As Phoenix Life Sciences International moves forward with company expansion in the new year, we are proud to recruit the most well-respected specialists in the growing industry, like Mohyuddin Mirza,” said Phoenix Life Sciences International CEO Martin Tindall. “Dr. Mirza’s growing expertise will be pivotal in building out the crop capacity to push forward our mission of transforming the future of global healthcare.”
Dr. Mirza has received numerous awards within the Alberta greenhouse industry and helped create the Alberta Greenhouse Growers Association. He is the author of hundreds of educational articles published in magazines like Greenhouse Canada and more recently Grow Opportunity.
“Considering the immense benefits of botanical pharmaceuticals in serving as an effective alternative for treating a wide range of conditions, I am proud to join Phoenix Life as it expands internationally,” said Dr. Mohyuddin Mirza. “I am looking forward to putting my decades of indoor growing expertise toward helping the company expand to help patients in need globally.”
To learn more about Phoenix Life Sciences International, please visit https://plsi.co/#about.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
FORWARD-LOOKING STATEMENTS
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.
LEGAL DISCLOSURE
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.